Catalent Inc. (NYSE:CTLT) has been given an average recommendation of “Hold” by the ten brokerages that are covering the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $27.80.
Several equities analysts have recently commented on the stock. Jefferies Group increased their price target on shares of Catalent from $25.00 to $28.00 and gave the stock a “hold” rating in a research report on Thursday, September 29th. Bank of America Corp. raised shares of Catalent from a “neutral” rating to a “buy” rating in a research report on Monday, June 20th. Finally, Wells Fargo & Co. raised shares of Catalent from a “market perform” rating to an “outperform” rating in a research report on Tuesday, June 21st.
A number of institutional investors have recently modified their holdings of the company. UBS Group AG boosted its position in shares of Catalent by 1.1% in the first quarter. UBS Group AG now owns 66,308 shares of the company’s stock worth $1,769,000 after buying an additional 712 shares in the last quarter. BlackRock Inc. boosted its position in shares of Catalent by 1.8% in the first quarter. BlackRock Inc. now owns 74,587 shares of the company’s stock worth $1,990,000 after buying an additional 1,319 shares in the last quarter. Forward Management LLC boosted its position in shares of Catalent by 8.7% in the first quarter. Forward Management LLC now owns 17,656 shares of the company’s stock worth $471,000 after buying an additional 1,411 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its position in shares of Catalent by 4.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 148,331 shares of the company’s stock worth $3,956,000 after buying an additional 5,743 shares in the last quarter. Finally, M&T Bank Corp acquired a new position in shares of Catalent during the first quarter worth about $207,000. 99.72% of the stock is currently owned by hedge funds and other institutional investors.
Catalent (NYSE:CTLT) opened at 25.94 on Friday. The firm has a market cap of $3.24 billion, a PE ratio of 29.15 and a beta of 1.41. Catalent has a 52-week low of $18.92 and a 52-week high of $32.24. The firm’s 50-day moving average price is $25.29 and its 200 day moving average price is $25.67.
Catalent Company Profile
Catalent, Inc is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Company’s segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.